Health
Crown Aesthetics Announces Groundbreaking Study on Skin Microbiome-Optimized BIOJUVE™ Regimen
Study Reveals Remarkable Results in Aesthetic Treatment Recovery DALLAS, Dec. 14, 2023 /PRNewswire/ -- Crown Aesthetics, a Crown Laboratories, Inc. company ("Crown"), announced today that its groundbreaking clinical study, recently accepted for publication in the Journal of Clinical and Aesthetic...
2023-12-14 03:56
1695
GREATER DES MOINES PARTNERSHIP ANNUAL DINNER SPEAKER ANNOUNCED
GREATER DES MOINES, Iowa, Dec. 13, 2023 /PRNewswire/ -- The Greater Des Moines Partnership has announced that its 2024 Annual Dinner will take place on Thursday, Jan. 25, 2024 at the Community Choice Credit Union Convention Center. The Partnership's Annual Dinner is the Greater Des Moines (DSM) bu...
2023-12-13 22:30
1646
COP28: Angel Yeast's Environmentally Friendly Yeast Protein Empowers Sustainability Development
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Angel Yeast
2023-12-13 22:04
3079
Immunocan Provides Update on Business Operations, Highlighting Launch of New Gene-edited Mice Generating Fully Human Heavy-chain-only Antibodies and Advances in Partner Pipeline
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Shanghai Immunocan Biotech Co., Ltd. ("Immunocan") announcesthe launch of its ImmuMab Heavy® mice. These gene-edited mice, developed by modifying the constant region genes of heavy chains in the ImmuMab® mouse, generate fully human heavy-chain-only antibodi...
2023-12-13 22:00
1936
Molecular Loop Biosciences Receives $1.8 Million to Expand Multi-pathogen Genomics Products for Respiratory Infections
WOBURN, Mass., Dec. 13, 2023 /PRNewswire/ -- Molecular Loop Biosciences, Inc., an innovator at the forefront of targeted sequencing technologies, is pleased to announce that it has received a$1.8 million grant from the Bill & Melinda Gates Foundation to further its groundbreaking work in the fiel...
2023-12-13 21:00
1650
Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent
MELBOURNE, Australia and SAN DIEGO, Dec. 13, 2023 /PRNewswire/ -- Imagion Biosystems Limited (ASX: IBX) recently announced positive results following completion of the IBI10103 phase I clinical trial evaluating the safety and clinical feasibility ofMagSense® HER2 Imaging Agent (MSH2IA) as an adju...
2023-12-13 19:00
1895
Transcenta Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging
PRINCETON, N.J. and SUZHOU, China, Dec. 13, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces ...
2023-12-13 18:01
2242
Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® 's Seventh Indication and BYVASDA®'s Eighth Indication
ROCKVILLE, Md. and SUZHOU, China, Dec. 13, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-12-13 12:56
3110
Millions of Australian kids at risk as families struggle to cool dangerously hot homes in cost of living crisis
SYDNEY, Dec. 13, 2023 /PRNewswire/ -- As another record-setting summer
approaches, millions of Australian families will be unable to keep their kids
cool in dangerously hot homes, with cost-of-living pressures stretching
households to the financial limit, a new report from Parents for Climate
2023-12-13 08:00
1732
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate
--First Chinese RSV PreF Vaccine Candidate to Enter Clinical Trial Stage--
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
2023-12-13 07:42
1859
The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the NDA for new indication of HANSIZHUANG, serplulimab, an innovative anti-PD-1 mAb independently developed by the company, in combination with chemotherapy as a first-line treatment for patients with...
2023-12-12 20:30
2206
Dr. Eliza Fok, Chairman of the Hong Kong Breast Cancer Foundation Is Honoured with "Women of Power 2023" by Prestige Hong Kong
HONG KONG, Dec. 12, 2023 /PRNewswire/ -- Hong Kong Breast Cancer Foundation (HKBCF) is proud to announce that Dr. Eliza Fok, Chairman of HKBCF, has been honoured with "Women of Power 2023" by leadingHong Kong magazine Prestige Hong Kong. HKBCF extends its congratulations to Dr. Fok on this achie...
2023-12-12 17:58
1724
Illumina partners with HaploX to build a domestically produced flagship benchtop sequencing system
SHENZHEN, China, Dec. 12, 2023 /PRNewswire/ -- On December 9, Illumina, a global leader in DNA sequencing and array-based technologies, and HaploX, aChina -based high-tech company specializing in oncology liquid biopsy and genetic big data, jointly announced the official launch of the first NextSe...
2023-12-12 17:31
2427
ICP DAS - BMP's Medical-Grade TPU Takes Center Stage at Top Global Medical & Plastic Exhibitions
HSINCHU, Dec. 12, 2023 /PRNewswire/ -- ICP DAS (3577-TW) New Business Unit, ICP DAS – BMP, actively ramps up medical-grade TPU (thermoplastic polyurethane) development and production as well as international marketing. The company's participation at COMPAMED and IPF Japan has been a resounding su...
2023-12-12 16:51
2467
Musim Mas Launched Women Smallholders Training Program
An expansion of the group's longstanding Smallholders Program, the first phase covered health and nutrition training; will be expanded to include financial literacy SINGAPORE, Dec. 12, 2023 /PRNewswire/ -- The Musim Mas Group announced the completion of the first phase of its Women Smallholders ...
2023-12-12 16:00
1674
Qilu Pharmaceutical Announces Results from Phase I Clinical Study for Its Novel Bispecific Antibody QLS31905 at ESMO Immuno-Oncology Congress
JINAN, China, Dec. 12, 2023 /PRNewswire/ -- During the ESMO Immuno-Oncology Congress 2023 held inGeneva, Switzerland, from December 6th to 8th, Qilu Pharmaceutical presented the latest results of the Phase I clinical trial for QLS31905 in patients with advanced solid tumors through a poster prese...
2023-12-12 11:04
1939
Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium
* ELEVATE and ELECTRA studies were designed with the objective to overcome different treatment resistance mechanisms and enhance patient outcomes with oral-oral combination options. * A preliminary analysis of data in the phase 1b part of the ELEVATE trial demonstrates antitumor activity of t...
2023-12-12 00:42
2749
Inovalon Applauded by Frost & Sullivan for Improving Healthcare Delivery, Patient Outcomes, and Data Security with Its Inovalon ONE® Platform
Inovalon ONE® Platform seamlessly aggregates, standardizes, and analyzes diverse data to gain meaningful insights, support evidence-based decision-making, and offer data security and privacy. SAN ANTONIO, Dec. 11, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the healthcare analytics...
2023-12-11 22:00
1516
First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging Agent
MELBOURNE, Australia and INDIANAPOLIS, Dec. 11, 2023 /PRNewswire/ -- Telix
Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the
first patient has been dosed in aUnited States (U.S.) expanded access program
(EAP, ClinicalTrials.gov ID:NCT06090331
2023-12-11 19:40
1460
Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle Maki as Chief Business Officer
SAN FRANCISCO and SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Offi...
2023-12-11 18:00
1634
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8873
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7709